Alex Biese

The FDA approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Braftovi with Erbitux and chemotherapy.

MammaPrint and BluePrint tests may help identify HR+/HER2– early-stage breast cancer patients likely to benefit from anthracycline-based chemotherapy.

The FDA accepted a new drug application for gedatolisib for patients with HR+, HER2-, PIK3CA wild-type advanced breast cancer.

In patients with high-risk melanoma, intismeran autogene and Keytruda reduced the risk of recurrence or death compared to Keytruda alone.

Patients with relapsed/refractory diffuse large B-cell lymphoma who received Epkinly alone experienced an improvement in progression-free survival.

This guide is designed to provide you with a clear medical foundation so you can engage in informed, collaborative discussions with your oncology team.

CURE sat down with Dr. Surbhi Sidana to discuss this treatment combination and what its approval by the FDA would mean for patients.

In patients with relapsed/refractory multiple myeloma, Tecvayli monotherapy is associated with a 71% reduction in the risk of disease progression or death.

CURE sat down with Dr. E. Antonio Chiocca to discuss a new brain cancer treatment being studied in an ongoing clinical trial.

Prostate cancer survivors Ronald Wakefield and Ernie Strauss sat down for an interview with CURE.

Bill Potts, a five-time cancer survivor, likes to refer to himself as “the luckiest guy I know.”

After Donna Rigby visited the emergency department at Hackensack Meridian Jersey Shore University Medical Center, tests showed stage 2 lung cancer.

Understanding your diagnosis, the tests ahead and the treatment landscape is the first step in regaining a sense of control.

These were the top gastrointestinal cancer stories published by CURE in 2025.

Dr. Erika Hamilton sat down for an interview with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

The NCCN hosted a Patient Advocacy Summit to address elevated cancer risks and specific healthcare needs of veterans and first responders.

Education is a vital step in navigating gallbladder cancer care.

Subgroup analysis of the phase 3 FOCUS study of patients with uveal melanoma has been announced.

CURE spoke with Dr. Natalie S. Berger for the latest episode of the "Cancer Horizons" podcast.

CURE spoke with an expert about smoking-related stigmas often faced by patients with lung cancer.

“Full House” star Dave Coulier, now undergoing treatment for tongue cancer, sat down for an interview with CURE.

Despite its vital function in many patients’ cancer journeys, palliative care is still the subject of several persistent myths and misconceptions.

A diagnosis of anal cancer can feel overwhelming, but understanding the disease is the first step toward effective management and recovery.

Dispelling myths and misconceptions and shedding light on disparities in hospice care.

Actor Dave Coulier, best known for his role in the sitcom “Full House,” recently sat down with CURE to discuss facing cancer for the second time.

The FDA granted regular approval to treatment with Rubraca for some adult patients with previously-treated metastatic castration-resistant prostate cancer.

CURE contributor Brian Sluga discusses his new memoir, “The Shriek I Do Remember.”

The FDA has approved Enhertu and Perjeta for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.